Italian MS patients on mayzent show promise in slowing disability over 3 years
NCT ID NCT05376579
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 134 adults in Italy with active secondary progressive multiple sclerosis who were prescribed siponimod (Mayzent) as part of their routine care. Over 36 months, researchers measured how many patients experienced a confirmed worsening of disability or cognitive decline. The goal was to see if the drug helps control the disease and slow progression in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Ancona, AN, 60126, Italy
-
Novartis Investigative Site
L’Aquila, AQ, 67100, Italy
-
Novartis Investigative Site
Bergamo, BG, 24127, Italy
-
Novartis Investigative Site
Bologna, BO, 40124, Italy
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Como, CO, 22100, Italy
-
Novartis Investigative Site
Catanzaro, CZ, 88100, Italy
-
Novartis Investigative Site
Foggia, FG, 71122, Italy
-
Novartis Investigative Site
Genova, GE, 16132, Italy
-
Novartis Investigative Site
Messina, ME, 98124, Italy
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Palermo, PA, 90127, Italy
-
Novartis Investigative Site
Padova, PD, 35128, Italy
-
Novartis Investigative Site
Pisa, PI, 56126, Italy
-
Novartis Investigative Site
Pavia, PV, 27100, Italy
-
Novartis Investigative Site
Roma, RM, 00133, Italy
-
Novartis Investigative Site
Roma, RM, 00152, Italy
-
Novartis Investigative Site
Roma, RM, 00189, Italy
-
Novartis Investigative Site
Orbassano, TO, 10043, Italy
-
Novartis Investigative Site
Trieste, TS, 34149, Italy
-
Novartis Investigative Site
Vicenza, VI, 36100, Italy
-
Novartis Investigative Site
Naples, 80131, Italy
-
Novartis Investigative Site
Naples, 80138, Italy
-
Novartis Investigative Site
Novara, 28100, Italy